Latest Intellectual Property News

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Next Science Limited has agreed to sell most of its assets to Demetra Holdings for US$50 million, with plans to return an estimated US$30 million net proceeds to shareholders pending approval.

ClearVue Technologies has secured $746,574 through a mix of equity and debt to support its international commercialisation efforts amid shifting market conditions.

Metallium Ltd has raised A$50 million to accelerate the commercial launch of its patented Flash Joule Heating technology in the U.S., aiming to revolutionize strategic metal recovery from waste and ore. The company is set to commission its first commercial plant in Texas by early 2026, backed by key partnerships and strong institutional support.

Proteomics International has achieved a major milestone with the first worldwide patent granted in Japan for its PromarkerEndo blood test, designed to diagnose endometriosis early and accurately.

Papyrus Australia reported a modest net operating cash outflow of $39,000 for May 2025, maintaining a solid cash position supported by available loan facilities that extend its funding runway to over 16 months.

Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.

Anagenics Limited’s licensed brand Bouf Haircare is outperforming expectations with strong early sales and promising royalty returns, signaling robust growth potential for the company’s intellectual property portfolio.

HyTerra Limited expands its Nemaha Project drilling program by adding a third well, McCoy 1, marking a shift to data-driven site selection. Early gas logs from Blythe 13-20 suggest promising hydrogen and helium presence, pending lab confirmation.

Neometals’ joint venture Reed Advanced Materials has signed a non-binding MoU with Rio Tinto to collaborate on advancing the ELi Process, a lithium hydroxide production technology promising significant cost and environmental benefits.

Neuren Pharmaceuticals has been granted a US patent for NNZ-2591 to treat Pitt Hopkins syndrome, bolstered by promising Phase 2 clinical trial results and FDA orphan drug status.